About, Dr. Vijay Patil
Dr. Vijay Patil is a well-experienced Medical Oncologist with 16 years of experience currently working at P. D. Hinduja Hospital, Mumbai, and has managed to achieve a broad spectrum of cancer conditions. He is considered to be the leading pioneer in the field of medical oncology who has revolutionized cancer treatments with his advanced research and studies.
Specialization
Dr. Vijay Patil is specialized in the following interventions –
- Head & Neck cancers
- Brain tumors
- Thoracic (Lung, Esophagus, Thymoma)
- Urological malignancies (Kidney, Urinary bladder, Prostate & Penile Cancer)
Education
- MBBS from Seth GS Medical College and KEM Hospital in 2006.
- MD in Radiation Oncology from PGI Chandigarh in 2009.
- Super-specialization in Medical Oncology from Tata Memorial Cancer Center, Mumbai in 2013.
Career
Dr. Vijay Patil has gained 16 years of experience in Medical Oncology. He started his career as an Assistant Professor at Malabar Cancer Center, Kerela, endeavored for 18 months, and provided quality and excellence in teaching. Later, he returned to Tata Memorial Hospital, Mumbai, and started from the rank of assistant professor to associate professor to professor in just 5 years. In addition to that, he also contributed to treating patients with cancer health concerns. Overall, to date, he has treated 1 Lakh cancer patients. Regulated and administered 1000 immunotherapy injections, 10,000 targeted therapy injections, Metronomic Chemotherapy injections in 15,000 patients, and Chemotherapy for 50,000 patients.
Advanced Developments in Medical Technology
Endured recent advancements in technologies for the treatment of head & neck, Thoracic, Neuro-Oncology, Gastrointestinal, Breast, Gynecological, and Uro-Oncology cancer which was curated by Dr. Vijay Patil. With the help of Dr. Kumar Prabhash conceptualized the development of immunotherapy, chemotherapy, and palliative treatments with safety and high-level of efficacy.
Publications
Dr. Vijay Patil has been actively involved in research and has authored 500 publications both nationally and internationally in medical oncology. He has revolutionized treatment criteria in the cancer domain. His recent publications in the field are –
- Long-term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.
- Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomized open-label phase II trial.
- Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
- A competing risk analysis of death patterns in male genitourinary cancer
- Role of palliative chemotherapy and targeted therapy in advanced esophageal and gastroesophageal junction cancers
- Change in Pattern of Failure in Head and Neck Cancer
- Real-world evidence for use of NACT in locally advanced external auditory canal cancer.
- Real-world data of the use of nivolumab in platinum-refractory head and neck cancers.
Awards
Dr. Vijay Patil has won several honors and awards over a period of time while servicing various hospitals & centers
- SHRI VIJAY BATRA RESEARCH FOUNDATION (ADLEY GROUP) AWARD for the year 2022
- FHNO Best Paper Award 2019
- ISMPO best paper- Kala Venkat award 2016
- ICON best geriatric case award 2014
- ISO best paper award in ICC 2013
- ASCO- IDEA AWARD 2014
- Best of ASCO India award 2014
- Best poster award in ISO conference, Bhubaneswar 2011
Research projects
Dr. Vijay Patil has carried out extensive research on Medical Oncology that is groundbreaking and transformative in the cancer domain
- Patil V, Noronha V, Dhumal SB, et al. Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomized, phase 3 trial. Lancet Glob Health 2020;8(9):e1213–22.
- Patil VM, Noronha V, Joshi A, et al. Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer. J Clin Oncol 2019; JCO1901076.
- Joshi A, Patil VM, Noronha V, et al. Results of phase II randomized controlled clinical trial comparing the efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer. J Clin Orthod 2017;35(15_suppl):6018–6018.
- Krishna VM, Noronha V, Prabhash K, et al. Sunitinib in metastatic renal cell carcinoma: a single-center experience. Indian J Cancer 2013;50(3):268–73.
- Noronha V, Joshi A, Muddu VK, Maruti Patil V, Prabhash K. Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre. Case Rep Oncol 2016;9(2):506–15.
- Agarwala V, Ramaswamy A, Joshi A, et al. Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis. South Asian J Cancer 2018;7(4):226–30.
- Chakraborty S, Geetha M, Dessai S, Patil VM. How well do elderly patients with cervical cancer tolerate definitive radiochemotherapy using RapidArc? Results from an institutional audit comparing elderly versus younger patients. Ecancermedicalscience 2014;8:484.
- Bajpai J, Susan D, Patil V, et al. Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India. Indian J Med Paediatr Oncol 2017;38(1):18–21.
- Patil V, Noronha V, Joshi A, et al. Distress Management in Patients With Head and Neck Cancer Before Start of Palliative Chemotherapy: A Practical Approach. J Glob Oncol 2018;(4):1–10.
A leading pioneer in Medical oncology that has associated with the research, studies, and training endeavors for the development in the field of cancer therapies. Recognized as one of the top oncologists in Mumbai that has brought significant change in technologies by gaining global acknowledgment for his contribution. In addition to that, he consolidated and administered treatment regimens at affordable cost with no compromise on quality and safety. On the whole, he has set a foundation in the medical oncology world by gaining recognition from national and international researchers for revolutionary endowments.